1037309-45-7 Usage
Uses
Used in Pharmaceutical Industry:
Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]-, succinate salt is used as a pharmaceutical compound for its potential therapeutic properties. Its unique structure may allow it to interact with biological targets, offering new avenues for the development of drugs to treat various diseases and conditions.
Used in Research Applications:
In the research field, Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]-, succinate salt serves as a valuable chemical entity for studying its interactions with biological systems. It can be used to investigate its binding affinity, selectivity, and potential mechanisms of action, contributing to the advancement of scientific knowledge in chemistry and biology.
Used in Chemical Industry:
Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]-, succinate salt may also find applications in the chemical industry as an intermediate or building block for the synthesis of other complex molecules. Its unique structure and properties can be leveraged to create new compounds with specific functions or improved performance in various applications.
It is crucial to handle Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]-, succinate salt with care and adhere to proper safety protocols when working with Quinoline, 2-[[4-[1-Methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]Methyl]- ,succinate salt to ensure the safety of individuals and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 1037309-45-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,7,3,0 and 9 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1037309-45:
(9*1)+(8*0)+(7*3)+(6*7)+(5*3)+(4*0)+(3*9)+(2*4)+(1*5)=127
127 % 10 = 7
So 1037309-45-7 is a valid CAS Registry Number.
1037309-45-7Relevant articles and documents
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3- yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia
Verhoest, Patrick R.,Chapin, Douglas S.,Corman, Michael,Fonseca, Kari,Harms, John F.,Hou, Xinjun,Marr, Eric S.,Menniti, Frank S.,Nelson, Frederick,O'Connor, Rebecca,Pandit, Jayvardhan,Proulx-LaFrance, Caroline,Schmidt, Anne W.,Schmidt, Christopher J.,Suiciak, Judith A.,Liras, Spiros
experimental part, p. 5188 - 5196 (2010/03/01)
By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique "selectivity pocket" for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties led to the discovery of 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920). This PDE10A inhibitor is the first reported clinical entry for this mechanism in the treatment of schizophrenia.
SUCCINATE SALT OF 2-((4-(1-METHYL-4-(PYRIDIN-4-YL)-1H-PYRAZOL-3-YL) PHENOXY)METHYL)QUINOLINE
-
Page/Page column 17, (2008/12/07)
The present invention relates to a succinate salt of 2-((4-(1-methyl-4- (pyridin-4-yl)-1 H-pyrazol-3-yl)phenoxy)methyl)quinoline, and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal the succinate salt. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and the succinate salt.
